Logo 1 Logo 2

Clinical Trial Details

Trial ID: L1626
Source ID: NCT00081471
Associated Drug: Darbepoetin Alfa
Title: A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Anemia
Interventions: DRUG: darbepoetin alfa|DRUG: methoxy polyethylene glycol-epoetin beta [Mircera]
Outcome Measures: Primary: Hemoglobin response rate, Weeks 1-28 | Secondary: Hb concentration over time, time to target Hb response, incidence of RBC transfusions. Vital signs, ECG, adverse events, laboratory values\n\n, Throughout study
Sponsor/Collaborators: Sponsor: Hoffmann-La Roche
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE3
Enrollment: 324
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2004-06
Completion Date: 2006-07
Results First Posted:
Last Update Posted: 2016-11-02
Locations: Los Angeles, California, 90073, United States|Mather, California, 95655, United States|Stanford, California, 94305-5114, United States|Stamford, Connecticut, 06902, United States|Bay Pines, Florida, 33744, United States|Ocala, Florida, 34471, United States|Shreveport, Louisiana, 71101, United States|Boston, Massachusetts, 02135, United States|Boston, Massachusetts, 02215, United States|Detroit, Michigan, 48236, United States|Flushing, New York, 11355, United States|Cincinnati, Ohio, 45220, United States|Portland, Oregon, 97201-2940, United States|Allentown, Pennsylvania, 18103, United States|Columbia, South Carolina, 29209, United States|Nashville, Tennessee, 37232, United States|Austin, Texas, 78705, United States|Dallas, Texas, 75216, United States|Houston, Texas, 77054, United States|Burlington, Vermont, 05401, United States|Salem, Virginia, 24153, United States|Morgantown, West Virginia, 26506, United States|Clayton, 3186, Australia|Liverpool, 1871, Australia|Parkville, 3052, Australia|Perth, 6847, Australia|Antwerpen, 2060, Belgium|Leuven, 3000, Belgium|Calgary, Alberta, T2N 2T9, Canada|Edmonton, Alberta, T6G 2B7, Canada|Kamloops, British Columbia, V2C 2T1, Canada|New Westminster, British Columbia, V3L 3W7, Canada|Vancouver, British Columbia, V6Z 1Y6, Canada|Winnipeg, Manitoba, R2H 2A6, Canada|St. John's, Newfoundland and Labrador, A1B 3V6, Canada|Kitchener, Ontario, N2G 1N9, Canada|London, Ontario, N6A 5A5, Canada|Scarborough, Ontario, M1H 3G4, Canada|Toronto, Ontario, M4N 3M5, Canada|Toronto, Ontario, M5G 2C4, Canada|Montreal, Quebec, H1T 2M4, Canada|Montreal, Quebec, H3A 1A1, Canada|Saskatoon, Saskatchewan, S7K 1N4, Canada|Angers, 49933, France|Besancon, 25030, France|Chartres, 28000, France|Colmar, 68024, France|Lille, 59037, France|Lyon, 69437, France|Nantes, 44035, France|Paris, 75743, France|Paris, 75908, France|Perpignan, 66046, France|Salouel, 80480, France|Toulouse, 31059, France|Vandoeuvre-les-nancy, 54511, France|Aschaffenburg, 63741, Germany|Berlin, 13353, Germany|Bonn, 53127, Germany|Dortmund, 44263, Germany|Düsseldorf, 40225, Germany|Tübingen, 72076, Germany|Alexandroupolis, 68100, Greece|Athens, 11527, Greece|Ioannina, 455 00, Greece|Piraeus, 18536, Greece|Thessaloniki, 54629, Greece|Cagliari, 91034, Italy|Cuneo, 12100, Italy|Genova, 16132, Italy|Lecco, 23900, Italy|Lodi, 26900, Italy|Modena, 41100, Italy|Napoli, 80131, Italy|Padova, 35128, Italy|Pavia, 27100, Italy|Prato, 50047, Italy|Reggio Calabria, 89124, Italy|Roma, 00184, Italy|Amersfoort, 3818, Netherlands|Heerlen, 6419 PC, Netherlands|San Juan, 00936-5067, Puerto Rico|Almería, 04009, Spain|Barcelona, 08907, Spain|Lerida, 25198, Spain|Madrid, 28041, Spain|Madrid, 28046, Spain|Madrid, 28805, Spain|Palma de Mallorca, 07014, Spain|Valencia, 46017, Spain|Boras, 50142, Sweden|Umea, 90185, Sweden|Birmingham, B9 5SS, United Kingdom|Carshalton, SM5 1AA, United Kingdom|Leicester, LE5 4PW, United Kingdom|London, SE1 9RT, United Kingdom|London, SE22 8PT, United Kingdom|London, SW17 0RE, United Kingdom
URL: https://clinicaltrials.gov/show/NCT00081471

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress